Thermally Responsive Magnetic-Hydrogel Nanocomposites for Advanced Drug Delivery

用于先进药物输送的热响应磁水凝胶纳米复合材料

• 批准号: 8242598
• 负责人: NICHOLAS A PEPPAS
• 金额: $ 21.21万
• 依托单位: UNIVERSITY OF TEXAS AT AUSTIN
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8242598
• 关键词: Address; Adsorption; Adverse effects; Affect; Antibodies; Behavior; Binding; Biomedical Engineering; Blood; Blood Circulation; Cell Surface Receptors; Cells; Characteristics; Charge; Deposition; Development; Diffusion; Dose; Drug Carriers; Drug Delivery Systems; Drug Transport; Encapsulated; Equilibrium; Ethylene Glycols; Fever; Frequencies; Gel; Gold; Half-Life; Heating; Hydrogels; Image; Immune; Immunoglobulin G; Implant; Kinetics; Light; Location; Magnetic Resonance Imaging; Magnetism; Medical Imaging; Metals; Modeling; Morphology; N-isopropylacrylamide; NanoGel; Nanosphere; Particulate; Penetration; Performance; Pharmaceutical Preparations; Pharmacotherapy; Photons; Physiological; Polymers; Positioning Attribute; Property; Proteins; Research; Research Personnel; Research Project Grants; Shapes; Solvents; Surface; Swelling; System; Systems Development; Temperature; Testing; Therapeutic; Therapeutic Agents; Time; Tissues; Work; absorption; base; biomaterial compatibility; chemical stability; clinically relevant; crosslink; density; design; environmental change; ethylene glycol; hydrophilicity; improved; in vitro testing; in vivo; iron oxide; magnetic field; metal oxide; nanocarrier; nanocomposite; nanomaterials; nanoparticle; nanoshell; novel; overexpression; particle; physical property; receptor; research study; response; solute; spatiotemporal; success; uptake

DESCRIPTION (provided by applicant): This is a revised proposal for an R21 Exploratory / Developmental Bioengineering Research Grant (EBRG) under PA-10-010 as an investigator-initiated application for developing a nanocomposite drug delivery system. The proposed drug delivery system consists of a degradable, thermally-responsive hydrogel nanosphere encapsulating a single domain paramagnetic iron oxide nanoparticle to release drug by swelling once magnetically-triggered. AC inductive heating of the magnetic nanoparticle conducts heat into the surrounding 'nanogel', which forces it to swell and imbibe physiological solvent. The swollen gel then releases incorporated drug agents for localized therapeutic delivery by diffusion and convective currents created during cyclical swelling and collapsing. The carriers will be designed for optimal in vivo targeting utility based on size, shape, charge, deformability, hydrophilicity, and degradability. Additionally, nanogel carriers will be surface modified for immune 'stealthing' to prolong circulation times, and with antibodies to facilitate active targeting. This composite drug delivery system can be used to concentrate therapeutics locally with release initiated by an external triggering mechanism and with enhanced medical imaging contrast if desired. In the development of this system, several fundamental challenges regarding nanogel drug delivery will be addressed. Specifically, the impact of temperature excursions and volume swelling responses will be examined to determine their impact on carrier stability, active targeting, and on non-specific protein adsorption. Furthermore, a novel testing apparatus will be fabricated that allows for swelling kinetics experiments as a function of carrier size. This will allow predictions to be made as to time to equilibrium and solute transport times with very small particulate carriers. Specific antibodies have been selected to enhance uptake by targeted cells overexpressing the desired receptor. Finally, nanocarriers will be tested in vitro to establish cytocompatibility, uptake performance, and required magnetic field strengths for triggering. PUBLIC HEALTH RELEVANCE: Drug therapies such as anticancer chemotherapeutics utilize toxic drugs which are typically administered systemically and therefore cause substantial unwanted side effects. Using nanocarriers, it is possible to deliver highly concentrated doses of these drugs at the anatomical locations where therapeutic benefit is greatest. An advanced nanocarrier system can be molecularly-targeted to the affected tissues, verified by imaging, and triggered externally for maximum control over treatment with greatly improved success rates.

描述（由申请人提供）：这是PA-10-010下的R21探索/开发生物工程研究资助（EBRG）的修订提案，作为开发纳米复合材料给药系统的申请。所提出的药物递送系统由可降解的热响应性水凝胶纳米球组成，该水凝胶纳米球封装单域顺磁性氧化铁纳米颗粒，一旦被磁触发就通过溶胀释放药物。磁性纳米颗粒的AC感应加热将热量传导到周围的“纳米凝胶”中，这迫使它膨胀并吸收生理溶剂。然后，溶胀的凝胶通过在周期性溶胀和塌陷期间产生的扩散和对流释放用于局部治疗递送的掺入的药物。将基于尺寸、形状、电荷、可变形性、亲水性和降解性设计载体以用于最佳体内靶向效用。此外，纳米凝胶载体将进行表面修饰，以进行免疫“隐身”，延长循环时间，并与抗体一起促进主动靶向。该复合药物递送系统可用于局部浓缩治疗剂，通过外部触发机制引发释放，并且如果需要，具有增强的医学成像对比度。 在该系统的开发中，将解决关于纳米凝胶药物递送的几个基本挑战。具体而言，将检查温度偏移和体积溶胀响应的影响，以确定其对载体稳定性、主动靶向和非特异性蛋白吸附的影响。此外，一种新的测试装置将被制造，允许作为载体尺寸的函数的溶胀动力学实验。这将允许预测的时间来平衡和溶质运输时间非常小的颗粒载体。已选择特异性抗体以增强过表达所需受体的靶细胞的摄取。最后，将在体外测试纳米载体以建立细胞相容性、摄取性能和触发所需的磁场强度。 公共卫生关系： 药物疗法如抗癌化学疗法利用毒性药物，其通常全身给药并因此引起大量不希望的副作用。使用纳米载体，可以在治疗益处最大的解剖位置递送高度浓缩剂量的这些药物。先进的纳米载体系统可以分子靶向受影响的组织，通过成像验证，并在外部触发，以最大限度地控制治疗，大大提高成功率。